Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2015-09-21 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Pharmaxis Investor Briefing - Drug Discovery 72 pages 3.5MB
Regulatory Filings
2015-09-21 English
PXS Releases Successful Phase Results of Phase 1 Trial 2 pages 127.9KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 22nd September 2015 announcing successful results from a Phase 1 clinical trial of a drug partnered with Boehringer Ingelheim. It contains no financial statements, regulatory form references, or detailed financial data. The content focuses on clinical trial results and company information rather than financial performance or regulatory filings. It is a press release announcing positive clinical trial outcomes, which does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or certification. Given the nature of the document as a media release announcing clinical trial results, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2015-09-21 English
Change in substantial holding 6 pages 272.0KB
Regulatory Filings
2015-09-09 English
Appendix 3B - exercise of employee options 12 pages 145.1KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class, number, terms, issue price, purpose, and quotation application for additional securities. It references ASX rules and compliance, and includes a quotation agreement section. The content is focused on the announcement and regulatory compliance related to the issuance and quotation of new shares/options, rather than a financial report or earnings release. This matches the definition of a Share Issue/Capital Change announcement, which covers new share issues and capital changes. The document length is substantial and contains detailed data, but it is not a financial report or management discussion. Therefore, the appropriate classification is 'SHA' (Share Issue/Capital Change).
2015-08-19 English
Preliminary Final Report 68 pages 769.0KB
Regulatory Filings
2015-08-18 English
Appendix 4G 11 pages 94.6KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which relate to corporate governance disclosures that must accompany the annual report. It includes a key to disclosures against the Corporate Governance Council Principles and Recommendations for the financial year ended 30 June 2015. The document is a detailed corporate governance statement or appendix that accompanies the annual report but is not the annual report itself. It primarily focuses on governance practices, board structure, and compliance with governance recommendations rather than financial performance or audit results. Given the content and regulatory references, this document fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2015-08-18 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.